rs786204471
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000057.4(BLM):c.2250_2251insAAAT(p.Leu751LysfsTer25) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000138 in 1,453,664 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000057.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000799 AC: 2AN: 250286Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135308
GnomAD4 exome AF: 0.0000138 AC: 20AN: 1453664Hom.: 0 Cov.: 29 AF XY: 0.0000124 AC XY: 9AN XY: 723404
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Bloom syndrome Pathogenic:8
- -
- -
- -
- -
Variant summary: BLM c.2250_2251insAAAT (p.Leu751LysfsX25) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 8e-06 in 250286 control chromosomes. c.2250_2251insAAAT has been reported in the literature in at-least two individuals with Bloom syndrome (German_2007) and in heterozygote carrier individuals tested in studies evaluating inherited DNA-repair defects in patients with colorectal cancer (AlDubayan_2018) and germline BLM mutations in metastatic prostate cancer (Ledet_2020). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic citing overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as pathogenic. -
The BLM c.2250_2251insAAAT (p.Leu751LysfsTer25) change results from the insertion of 4 nucleotides to cause a frameshift and the creation of a premature stop codon. This change is predicted to cause protein truncation or absence of the protein due to nonsense-mediated decay. This variant has been reported in the compound heterozygous state in two individuals with Bloom syndrome (PMID: 17407155). It has been reported in the heterozygous state in at least one individual with colorectal cancer (PMID: 29478780). This variant has a maximum subpopulation frequency of 0.0018% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). In summary, this variant meets criteria to be classified as likely pathogenic. -
- -
This sequence change creates a premature translational stop signal (p.Leu751Lysfs*25) in the BLM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BLM are known to be pathogenic (PMID: 17407155). This variant is present in population databases (rs786204471, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with Bloom's syndrome (PMID: 17407155). ClinVar contains an entry for this variant (Variation ID: 188790). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.2250_2251insAAAT variant, located in coding exon 9 of the BLM gene, results from an insertion of 4 nucleotides at position 2250, causing a translational frameshift with a predicted alternate stop codon (p.L751Kfs*25). This alteration has been detected in the compound heterozygous state in two individuals affected with Bloom syndrome (German J et al. Hum. Mutat. 2007 Aug;28:743-53). This alteration has also been detected in a patient affected with colorectal cancer (AlDubayan SH et al. Am. J. Hum. Genet. 2018 03;102:401-414). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at